Chondrosarcoma
Drug research and approvals for chondrosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 19 studies of chondrosarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest start dates first, of 19 recruiting on ClinicalTrials.gov ↗- Clinical Applicability of Liquid Biopsy in ChondrosarcomaNCT07492823 · Not reported · Medical University of Graz · starts Jun 1, 2026
- Diagnostic and Therapeutic Targets in Cartilaginous TumoursNCT07315542 · Not reported · St. Anne's University Hospital Brno, Czech Republic · starts May 1, 2025
- Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic SequencingNCT06749366 · Not reported · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · starts Jan 27, 2025
- PET-imaging of Two Vartumabs in Patients With Solid TumorsNCT06645808 · Early Phase 1 · Var2 Pharmaceuticals · starts Dec 10, 2024
- Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously…NCT06127407 · Phase 3 · Servier Bio-Innovation LLC · starts Jul 9, 2024
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and…NCT06239272 · Phase 1 / Phase 2 · St. Jude Children's Research Hospital · starts Mar 27, 2024
- Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNCT06176989 · Phase 2 · National Cancer Institute (NCI) · starts Mar 4, 2024
- A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningNCT06387485 · Not applicable · Ricoh USA, Inc. · starts Mar 1, 2024
- Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton TherapyNCT06029218 · Not applicable · Centre Antoine Lacassagne · starts Sep 13, 2023
- Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull BaseNCT05861245 · Not applicable · Quironsalud · starts May 24, 2023
Drug pipeline
8 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Everolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Pazopanib
- Phase 2 Macrophage colony stimulating factor receptor inhibitor
- Ivosidenib
- Phase 2 Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
- Imatinib
- Phase 2 Tyrosine-protein kinase ABL inhibitor
- Catequentinib
- Phase 2 Vascular endothelial growth factor receptor 2 inhibitor
- Patidegib
- Phase 2 Smoothened homolog antagonist
- Drozitumab
- Phase 2 Tumor necrosis factor receptor superfamily member 10B agonist
- Ozekibart
- Phase 2
- Zoledronic acid anhydrous
- Phase 1 Farnesyl diphosphate synthase inhibitor
- Tanespimycin
- Phase 1 Heat shock protein HSP90 inhibitor
How its trials ended
84 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 36% met their primary endpoint, 14% missed it and 50% stopped early.
- Ongoing3946%
- Completed, result not reported2833%
- Met its primary endpoint56%
- Stopped: other or unclear45%
- Status unknown34%
- Missed its primary endpoint22%
- Stopped: sponsor or business decision22%
- Stopped: enrollment or feasibility11%
Trials authorized in Canada
Newest first; search them all in Canada trials| May 16, 2024 | A phase 3, multicenter, doa phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants = 18 years of age with…Ivosidenib (AG-120, S95031) | Servier | Ongoing |
| Apr 23, 2021 | A phase 2 study of anti-PD-L1 antibody (atezolizumab) in chondrosarcoma and clear cell sarcomaAtezolizumab (MPDL3280A) | Princess Margaret Cancer Centre | Pending |
FDA orphan designations
Approved first, then open designations, newest first| May 17, 2023 | IvosidenibTreatment of Chondrosarcoma | Servier Pharmaceuticals | Designated |
| Nov 24, 2021 | OzekibartTreatment of Chondrosarcoma | Inhibrx, Inc. | Designated |
| Feb 18, 2011 | Oral potent and selective antagonistTreatment of patients with chondrosarcoma. | Infinity Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA